Close Menu

NEW YORK – The US Centers for Medicare and Medicaid Services has finalized the draft national coverage decision memo it issued last October, describing criteria for the coverage of blood-based colorectal cancer screening tests, but denying coverage for Epigenomics' Epi ProColon assay.

Apart from Epigenomics, the memo stands to impact a number of companies developing genomic and epigenomic blood tests for colorectal cancer including Guardant Health, Freenome, Exact Sciences, and others.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.